Goal is to empower physicians and patients through making whole genome sequencing broadly available
BOSTON, Jan. 8, 2018— Veritas Genetics, The Genome Company, and Mayo Clinic are entering into an agreement to make whole genome sequencing broadly available to healthy individuals.
As part of this collaboration:
- The team at Mayo Clinic’s Center for Individualized Medicine will provide medical and clinical expertise to the Veritas team.
- Veritas will integrate Mayo Clinic’s know-how into its flagship product myGenome.
- Patients who qualify for a Mayo Clinic research study of healthy adults will be offered Veritas myGenome screening test for whole genome sequencing.
- Mayo Clinic will become a shareholder of Veritas.
“The Center for Individualized Medicine at Mayo Clinic is the gold standard in personalized medicine and we are proud and honored to collaborate with such a professional and dedicated team. This is a great step to further realize the promise of the human genome,” expressed Mirza Cifric, Founder, CEO Veritas Genetics. [Read more…]
SINGAPORE, 3 January 2018 – Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”) has signed a sale and purchase agreement to acquire full control of HealthBaby Biotech (Hong Kong) Co., Limited (“HealthBaby Hong Kong”), in a move that will expand its presence in the private cord blood banking industry in Hong Kong and Macau. 
MADISON, Wis.,